Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck ditches oncolytic virus Cavatak

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Oct 27, 2022 9:57pm

147 Views

Post# 35054933

RE:RE:RE:RE:RE:RE:Merck ditches oncolytic virus Cavatak

Buckhenry wrote:
there are other sites for the overall biotech market... lets focus on oncy for a change.

I think discussion of potential competitors is important - it rounds out consideration of ONC's position in its natural environment. It all goes to build the bigger picture. What we need, though, is more reportage on successful competitors (if any)

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost